| Tubulointerstitial nephritis in IBD | ||
| Type | Description | Clinical Management |
| Drug-related nephrotoxicity | - Aminosalicylate and anti―TNF α-induced nephropathy - The incidence is one case per 4000 patients/years who received 5-AZA - Early detection of 5-AZA associated IN (<12 months) responds completely to drug withdrawal | Monitoring of kidney function by measuring: GFR Serum creatinine levels Urinary Levels of tubular markers (α1-MG, β-NAG, β2-MG) Assessment of serum creatinine of IBD patients prior to commencing drug therapy, monthly for the first 3 months, 3 monthly for the remainder of the year and then annually thereafter |
| EIM of IBD | - Not related to IBD drugs-nephrotoxicity - Occurrence in treatment-naive IBD patients or after drug discontinuation - Early discontinuation of 5-ASA supplemented by corticosteroid therapy is beneficial | |